› Forums › General Melanoma Community › Novartis melanoma combination wins key thumbs-up from cost watchdog NICE after Opdivo shut out
- This topic has 2 replies, 2 voices, and was last updated 6 years, 5 months ago by
MelanomaMike.
- Post
-
- September 18, 2018 at 5:24 pm
- Replies
-
-
- September 18, 2018 at 6:34 pm
Hi Anon, I find that the article doesn't give the full view of the adjuvant trials and approvals compared to the USA. For example the Nivo approval was a trial where standard of care Ipi at 10mg/kg was head to head compared to Nivo and Nivo came out way ahead in RFS and side effects toxicity profile. The targeted therapy trial used a placebo arm as a comparison why not go up against Ipi???? Here are two recent ONclive peer panel discussions on adjuvant treatment options and one specific to targeted therapy. https://www.onclive.com/peer-exchange/advanced-melanoma-paradigms/melanoma-braf-mek-inhibitors-as-adjuvant-therapy. https://www.onclive.com/peer-exchange/advanced-melanoma-paradigms/molecular-testing-in-melanoma-braf-and-pdl1
-
- September 19, 2018 at 10:38 pm
Get em’ Ed!
-
- You must be logged in to reply to this topic.